EGFR Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

EGFR Tests Market Report Overview

The EGFR tests market size was $17.4 million in 2023 and it will grow at a CAGR of less than 1% during 2023-2033. Epidermal growth factor receptor gene (EGFR) tests are carried out to detect mutations within this receptor gene in non-small cell lung cancer tumor cells. The outcome of may determine if EGFR-targeted tyrosine kinase inhibitors such as gefitinib and erlotinib may be beneficial for treating non-small cell lung cancer (NSCLC).

EGFR Tests Market Outlook, 2023-2033 ($ Billion)

Buy the Full Report for More Insights into the EGFR Tests Market Forecast

Download a Free Report Sample

The EGFR tests market research report gives a detailed overview of market behavior, which will help identify quantitative market trends in the anesthesia and respiratory devices therapeutic area. It discusses in detail the impact of COVID-19 on the EGFR tests market for the year 2020 and beyond. The report has extensively covered pipeline products and technologies, which will help in identifying companies with the most robust pipeline. This, in turn, will assist in predictive analysis for designing your in-licensing and out-licensing strategies.

EGFR Tests Market Dynamics

The market for EGFR tests will grow across all regions during the forecast period driven by several factors including increasing lung cancer incidence, greater disease awareness, improved accessibility to EGFR-TKIs in emerging economies, and technological advancements. There will be an increased usage of liquid biopsies in the future because of the benefits available for patients with metastatic recurrence. Some KOLs indicate that, despite some sensitivity issues, liquid biopsies are affordable, and the minimally invasive aspect of the technique improves patient satisfaction. Furthermore, increasing lung cancer incidence, greater disease awareness, improved accessibility to EGFR-TKIs in emerging economies, and technological advancements will fuel the EGFR tests market during the forecast period.

EGFR Tests Market Segments

The key segments in the EGFR tests market are EGFR immunohistochemistry tests, EGFR nucleic acid amplification tests (NAATs), EGFR sanger sequencing tests, and EGFR other tests. EGFR sanger sequencing tests accounted for the highest share of the EGFR tests market in 2023. They are carried out when complete sequencing of the epidermal growth factor receptor (EPGFR) gene is required for accurate detection and mapping of mutations in the gene sequence.

EGFR Tests Market Analysis by Segments, 2023 (%)

Buy the Full Report for More Segment Insights into the EGFR Tests Market

Download a Free Report Sample

EGFR Tests Market Segmentation by Regions

The key regions in the EGFR tests market are North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. In 2023, North America dominated the EGFR tests market. Factors driving EGFR testing in the region are the rising lung cancer incidence and the increasing popularity of targeted therapies.

EGFR Tests Market Analysis by Regions, 2023 (%)

Buy the Full Report for More Regional Insights into the EGFR Tests Market

Download a Free Report Sample

EGFR Tests Market - Competitive Landscape

A few of the leading companies in the EGFR tests market are:

• Hoffmann-La Roche Ltd
• Qiagen NV
• Agilent Technologies Inc
• Illumina Inc
• Thermo Fisher Scientific Inc

Qiagen NV dominated the market in 2023.

EGFR Tests Market Analysis by Companies, 2023 (%)

Buy the Full Report for More Company Insights into the EGFR Tests Market

Download a Free Report Sample

Segments Covered in the Report

EGFR Tests Segments Outlook (Value, $ Billion, 2015-2033)

• EGFR Immunohistochemistry Tests
• EGFR Nucleic Acid Amplification Tests (NAATs)
• EGFR Sanger Sequencing Tests
• EGFR Other Tests

EGFR Tests Regional Outlook (Value, $ Billion, 2015-2033)

• North America
• Europe
• Asia Pacific
• South and Central America
• Middle East & Africa

Key Inclusions

Currently marketed EGFR tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total EGFR tests market revenue by segment and market outlooks from 2015-2033.
• Market-level data on units, average selling prices, and market values.

Global, Regional, and Country level market specific insights:

• Qualitative market-specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
• SWOT analysis for the EGFR tests market.
• Competitive dynamics insights and trends provided for the EGFR tests market.

Get an in-depth understanding of consumer behavior through the market access segment and the overview of the healthcare system. The report also offers information on reimbursement policies and the regulatory landscape.

• Country-specific overview of the healthcare system.
• Country-specific reimbursement policies.
• Country-specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide an extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, the report helps determine market trends through real-world data sources including government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: F. Hoffmann-La Roche Ltd, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, NimaGen BV, Mesa Laboratories Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, HLB PanaGene Co Ltd, and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This report provides:

• Insightful review of the key industry trends.
• Annualized total EGFR tests market revenue by segment and market outlooks.
• Market-level data on units, average selling prices, and market values.
• Global, regional, and country-level market-specific insights including qualitative market-specific information with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
• SWOT analysis for the EGFR tests market.
• Competitive dynamics insights and trends provided for the EGFR tests market.
• Country-specific overview of the healthcare system.
• Country-specific reimbursement policies.
• Country-specific medtech regulatory landscape.

Reasons to Buy

• Understand the impact of COVID-19 on the EGFR tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the EGFR tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the EGFR tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company’s share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific EGFR tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.